Evidence map›Paper›PMID 25533300›Full record

SynthesisMultiple sclerosis (Houndmills, Basingstoke, England)2015

A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis.

Ruth Ann Marrie, Nadia Reider, Jeffrey Cohen, Olaf Stuve, Maria Trojano, Gary Cutter, Stephen Reingold, Per Soelberg Sorensen

Open access · hybridAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Multiple sclerosis (Houndmills, Basingstoke, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 7 pooled it
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 7 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Review
  10. Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Ruth Ann MarrieDepartment of Internal Medicine, University of Manitoba, Canada/Department of Community Health Sciences, University of Manitoba, Canada rmarrie@hsc.mb.ca.
Nadia ReiderDepartment of Internal Medicine, University of Manitoba, Canada.
Jeffrey CohenMellen Center for MS Treatment and Research, Cleveland Clinic, USA.
Olaf StuveDepartment of Neurology and Neurotherapeutics, University of Texas Southwestern, USA.
Maria TrojanoDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Italy.
Gary CutterDepartment of Biostatistics, University of Alabama at Birmingham, USA.
Stephen ReingoldScientific and Clinical Review Associates, LLC, USA.
Per Soelberg SorensenDepartment of Neurology, Copenhagen University Hospital Rigshospitalet, Denmark.
University of Manitoba · CACleveland Clinic · USRigshospitalet · DKThe University of Texas Southwestern Medical Center · USUniversity of Alabama at Birmingham · USUniversity of Bari Aldo Moro · IT

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundFindings regarding the prevalence of vascular comorbidities in multiple sclerosis (MS) are conflicting.

objectiveThe objective of this review is to estimate the incidence and prevalence of vascular comorbidities and predisposing comorbidities in persons with MS and to assess the quality of the included studies.

methodsThe PubMed, EMBASE, SCOPUS and Web of Knowledge databases, conference proceedings, and reference lists of retrieved articles were searched. One reviewer abstracted data using a standardized data collection form, while the second reviewer verified the abstraction. Included studies were assessed qualitatively. Quantitatively, we assessed studies using the I² statistic, and conducted meta-analyses for population-based studies only.

resultsThe prevalence of hypertension and hyperlipidemia exceeded 10% in the MS population and increased with age. While the prevalence of ischemic heart disease, congestive heart failure, and stroke were less than 5% overall, the prevalence of these conditions exceeded expectations when compared to the general population. Cardiac valvular disease, however, affected the MS population less often than expected. Problems with study quality were common.

conclusionDespite the relatively high prevalence of some vascular comorbidities in the MS population, important gaps exist in our understanding of their epidemiology. Most of our knowledge is based on studies conducted in a small number of regions.

Indexed as

Cerebrovascular DisordersComorbidityHeart DiseasesHumansIncidenceMultiple SclerosisPeripheral Vascular DiseasesPrevalencecardiaccomorbidityincidenceMultiple sclerosisperipheral vascular diseaseprevalencestrokesystematic review

Identifiers

PMID25533300
PMCPMC4404402
OpenAlexW2112063945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.